Neurologists are generally steeped in the
|
|
- Daniel Bruce
- 5 years ago
- Views:
Transcription
1 FEBRUARY A PAPER THAT CHANGED MY PRACTICE Gord Gubitz Queen Elizabeth II Health Sciences Centre, Halifax, Canada, B3H 3T7. ggubitz@is.dal.ca The NINDS trial of thrombolysis in acute ischaemic stroke Neurologists are generally steeped in the time-honoured tradition of making meticulous observations about individual patients. Our occasionally obsessive tendencies allow us to fixate on the details of a patient s history before performing a sophisticated physical examination, and (hopefully) arriving at a correct anatomical and pathological diagnosis for the particular problem. Recent technological advances have honed these diagnostic tools to an even finer edge. However, until fairly recently, the intellectual thrill of the neuro-diagnostic chase went unmatched by the satisfaction of delivering effective treatment, leading to the nice job but so what criticism often levelled at our speciality. To add a note of personal misgiving, the area within neurology that interests me most is stroke. I have lost track of the number of times that I have been told by other smug specialists, with a note of pity in their voices, that, It s all over as soon as the stroke has happened. Of course, in the not too distant past, a diagnosis of ischaemic stroke would have been viewed pessimistically by health care professionals, patients and families, because there were no proven curative therapies. Although a proper cure for stroke remains elusive, several recent interventions have been proven to save lives and reduce disability, including organized care on a multidisciplinary stroke unit (Stroke Unit Trialists Collaboration 2001), and aspirin therapy within the first 48 h of stroke onset (Chen et al. 2000). Increasingly, ischaemic stroke is being viewed as a medical emergency requiring urgent treatment (Hill & Hachinski 1998), with a resultant increase in the interest in stroke medicine, and research into newer and more effective treatments. These changes are both timely and important, as stroke remains a formidable global problem that is only going to worsen as our populations age.
2 46 PRACTICAL NEUROLOGY THE NINDS ACUTE STROKE TRIAL It is for this reason that, when asked to write about an article that has changed my practice, I immediately thought of the one study in the area of acute stroke that has caused the most international controversy and debate the National Institute for Neurological Diseases and Stroke (NINDS) trial of tissue plasminogen activator (TPA) for acute stroke (NINDS rt-pa Study Group 1995). Despite ongoing uncertainties surrounding the use of TPA, this trial has in many ways been the impetus for changing the way that we care for people with strokes. Some neurologists are now getting out of their beds in the middle of the night to go and see patients an activity that would have been almost unheard of a short decade ago. Some neurologists are now getting out of their beds in the middle of the night to go and see patients an activity that would have been almost unheard of a short decade ago Thrombolysis is one of the most exciting treatment options yet evaluated for acute stroke, because this is the only known therapy with the potential to actually reverse the stroke process. The use of clot busting drugs has a relatively long and successful history in the treatment of coronary artery disease (FTT Collaborative Group 1994), but, despite some early trials in the 1950s, has only been extensively studied in stroke patients for the past 10 years or so (Wardlaw and Warlow 1992). Following some early unsuccessful thrombolysis trials in acute stroke, the NINDS trial was eventually published in 1995 (NINDS rt-pa Study Group 1995), and TPA received approval from the American Food and Drug Association soon afterwards (Anonymous 1996a), with several sets of guidelines subsequently published (Adams et al. 1996; National Stroke Association 1993; Pessin et al. 1997). Because it was the first randomised controlled clinical trial to provide some evidence of benefit for an albeit highly selected group of people with acute stroke, the NINDS trial was received with tremendous enthusiasm in the United States, and enjoyed fairly extensive media coverage (Gorman 1996). The use of TPA even became part of the plot in an episode of ER, a popular American television programme (National Broadcasting Corporation 1997). In February 1999, the Therapeutic Products Directorate of Health Canada conditionally approved the use of TPA for acute stroke within three hours of symptom onset (Anonymous 1999a), a decision based primarily on the evidence provided by the American NINDS trial (NINDS rt-pa Study Group 1995). Canadian treatment guidelines were subsequently published (Norris et al. 1998), followed by the development of similar acute thrombolysis programmes in major Canadian centres (including my own), accompanied by national media coverage (Foss 1999; Evenson 1999; MacKinlay 1999). BUT, A NOTE OF CAUTION However, despite being heralded as a new standard of care by many, the increased use of TPA has not been universal, and this chemical neurosurgery remains a highly controversial subject. The actual frequency with which TPA is being given for acute ischaemic stroke in the United States is quite low, with only about 1.5% of eligible patients described as actually receiving it in one published report (Alberts 1998), although other postmarketing surveillance studies suggest slightly higher rates of use, but with few reports consistently above 5%. One reason for this rather poor showing may be the substantial variation in the attitudes of clinicians (neurologists, internal medicine specialists, geriatricians and emergency physicians) about the safety and applicability of TPA within and between different countries. Where I work in Canada, there are now two published sets of conflicting recommendations dealing with the use of TPA in acute ischemic stroke. Guidelines from the Canadian Stroke Consortium (Norris et al. 1998) are largely based on those from the American Heart Association (Adams et al. 1996) and advocate the use of TPA for patients who meet criteria largely specified in the NINDS trial (NINDS rt-pa Study Group 1995). On the other hand, recent recommendations from the Canadian Association of Emergency Physicians (CAEP 2001) are generally more conservative. The CAEP
3 FEBRUARY guidelines recommend that stroke thrombolysis should be limited to centres with appropriate neurological and neuro-imaging resources that are capable of administering treatment within 3 hours. In such centres, emergency physicians should identify eligible patients, initiate low risk interventions and facilitate prompt computed tomography. Only physicians with demonstrated expertise in neuroradiology should interpret head CT scans used to determine whether to administer thrombolytic agents to stroke patients. Neurologists should be directly involved prior to the thrombolytic administration. Other related problems include a lack of patient awareness of the symptoms and importance of stroke, and prehospital and hospital infrastructures that are presently at odds with the very short assessment and treatment window necessary for thrombolysis for stroke (Wester et al. 1999). As well as inciting debate in the medical literature (Brott et al. 1996; Caplan et al. 1998; Horowitz 1998; Li 1998; Anonymous 1996b), several general reviews and consensus statements (Gubitz et al. 1999; Anonymous 1999b; Royal College of Physicians of Edinburgh 1999; Anonymous 1997) have since been published that argue against the routine use of TPA for persons with acute ischaemic stroke, and have called for randomised trials to further evaluate this therapy. CONTINUING UNCERTAINTY It cannot be denied that the results of the NINDS TPA trial (NINDS rt-pa Study Group 1995) have transformed how many clinicians think about the management of some people with acute stroke. For me, one of the most beneficial outcomes of the NINDS trial has been the controversy that has resulted from it, and the genuine lack of certainty that I feel when confronted with an otherwise perfectly eligible patient three and a half hours after their stroke has started. I suspect that many of my colleagues feel the same way (even if they won t admit it!). Some patients I treat, but only within three hours, and only if I m certain. The majority of patients go untreated; I simply don t know what the correct action is, as many of my patients don t fit the general profile of those enrolled in the published trials. The patients I see are often older, with other medical problems, and many will have early changes (subtle and otherwise) on their CT scans. As I see it, uncertainty is a useful marker for the need for further understanding. If we are to make the best possible decisions about care for patients, it is important to systematically consider all of the available evidence rather than to rely on information from individual clinical trials. A systematic review of all the randomised evidence provides a more precise estimate of treatment-effect by reducing the effects of random error and systematic bias (Counsell et al. 1995). Such an approach may also explain inconsistencies between trials, and may generate new research questions. Uncertainty about the NINDS trial led me to seek further information about the complex and thorny issue of TPA in acute stroke by introducing me to a systematic review of all of the randomised trials of TPA in acute stroke (Wardlaw et al. 2001). The systematic review, published and updated on a regular basis on the Cochrane Library, includes 17 unconfounded, truly randomised clinical trials with a total of 5144 patients comparing intravenous thrombolytic treatment with placebo in patients with acute ischemic stroke of less than 6 h duration (Wardlaw et al. 2001). In all trials, a computed tomographic (CT) or magnetic resonance (MR) scan was performed before randomization to exclude intracranial haemorrhage or structural stroke mimics. The systematic review included information on three different thrombolytic agents: streptokinase, urokinase and TPA. Over 50% of the data (2889 patients, including the NINDS trial) compared TPA with control in acute ischemic stroke. In the systematic review (Wardlaw et al. 2001), the absolute risk of symptomatic intracranial haemorrhage was increased in the TPAtreated group, corresponding to 73 additional symptomatic haemorrhages for every 1000 patients treated with TPA (95% CI additional haemorrhages). However, the number of patients dead or dependent at the end of the follow-up period (considered by many to be the most important outcome) was markedly reduced. The systematic review demonstrated that 57 additional patients (95% CI 20 93) were alive and independent at the end of follow-up for every 1000 patients treated with thrombolysis within six hours of stroke onset. By way of comparison, thrombolysis for acute myocardial infarction results in an absolute mortality reduction of 30 per 1000 if treatment is given within the first 6 h of symptom onset (FTT Collaborative Group 1994). A subgroup analysis suggested that the balance of risk and benefit may be related to the
4 48 PRACTICAL NEUROLOGY timing of TPA administration, with a more favourable outcome if TPA is given within three hours of onset. It should be recognized that this subgroup analysis was based on data from only 869 patients from three trials (Anonymous 1996a; Cochrane Stroke Review Group 1999; Hacke et al. 1995), with the NINDS trial (Anonymous 1996a) contributing over 50% of the information. In addition, the authors of the review speculated upon imbalances in the baseline variables that could have introduced other biases. Despite these limitations, the reduction in the number of patients dead or dependent at the end of follow-up was striking, which, if proven to be true, would be consistent with 140 additional patients alive and independent for every 1000 patients treated with TPA within three hours of stroke onset (95% CI more patients with a good recovery; 2P = ). It is worth noting that the number for the NINDS trial alone was 160 additional independent survivors; 95% CI The systematic review (Wardlaw et al. 2001) demonstrated a trend for greater benefit if TPA was given earlier on, but no obvious cut off point at which TPA stops being effective was identified. There may be benefits beyond the three-hour time window. Unfortunately, the time at which the risk of TPA outweighs the benefits is not known; there is insufficient randomised evidence at present to state this with any certainty. At face value, this is very striking. A treatment-effect of this magnitude has never before been seen in acute stroke. However, this result is largely due to a difference of only 50 fewer dead or dependent patients in the TPA treated group of the NINDS trial (the only positive trial). The estimate of the treatment-effect, although statistically significant, is not very robust, and could be altered completely by comparatively small changes in the raw data. Estimates based on a small number of outcome events are more likely to be subject to bias (systematic error) and the play of chance (random error) than estimates based on a large number of outcome events. Indeed, further analysis of this threehour data demonstrates a statistically significant difference (heterogeneity) between the results of the three trials implying that factors other than chance are at play. While it is possible to speculate on the potential cause(s) of this heterogeneity, the differences cannot be adequately explained by the existing data. Therefore, while the data cannot be disputed, it is reasonable to caution against over-emphasis of the results of one very positive trial. THE NEED FOR MORE RANDOMISED TRIALS It has been demonstrated that TPA given to (highly selected) patients in specialist centres within three hours of acute ischaemic stroke onset reduces the overall risk of death and dependency in the long term, but this benefit may be offset somewhat by an increased short-term risk of intracranial haemorrhage. Despite the recent licensing of TPA and the development of treatment guidelines in North America, the balance between the risks and benefits from thrombolysis in acute ischaemic stroke remains in many ways unclear. It is still not clear exactly which stroke patients stand to benefit from or be harmed by TPA. More data are needed to clarify the time window during which TPA can be safely administered, the role of initial stroke severity, the significance of early visible ischaemic changes on CT scan, the use of TPA in older patients, the generalisability of thrombolysis in less experienced centres and the cost effectiveness of TPA. The answers to the questions posed in the systematic review will only be found in further research. One solution to the uncertainty created by the NINDS trial is a new randomised trial sufficiently powered to deal with the unresolved questions. Our stroke group in Halifax is becoming involved in just such a trial. The Third International Stroke Trial (IST-3) is an international, multicentre, randomised, double-blind, placebo-controlled trial of TPA in acute stroke presenting up to six hours after symptom onset. The trial is presently in the pilot phase, and is recruiting interested centres for the main phase of the trial. The IST-3 plans to randomise at least 6000 patients from both urban and rural centres. Further information about the IST-3 may be obtained from the IST-3 website: REFERENCES Adams HJP, Brott TG, Furlan AJ et al. (1996) Guidelines for thrombolytic therapy for acute stroke: a supplement to the guidelines for the management of patients with acute ischaemic stroke: a statement for healthcare professionals from a Special Writing Group of the Stroke Council, American Heart Association. Circulation, 94, Alberts M (1998) tpa in acute ischemic stroke. United States experience and issues for the future. Neurology, 51, S53 S55.
5 FEBRUARY Anonymous (1996a) FDA committee clears Activase for stroke. Scrip, 2137, 24. Anonymous (1996b) Panel Discussion at the 4th International Symposium on Thrombolytic Therapy. Thrombolysis for Stroke Time for a Consensus. Cerebrovascular Disease, 6, Anonymous (1997) Optimising Intensive Care in Stroke: a European Perspective. A Report of an Ad Hoc Consensus Group Meeting. Cerebrovascular Disease, 7, Anonymous (1999a) Canadian Adverse Drug Reaction Newsletter: Alteplase (Activase rt-pa) for acute ischemic stroke: special precautions for new indication. CMAJ, 161, Anonymous (1999b) The 1998 Karolinska Stroke Update Consensus Statements. In: Update on Stroke Therapy 1998/1999 (Wahlgren N & von Arbin M, eds), pp Karolinska Stroke Update, Stockholm. Available online at CAEP Committee on Thrombolytic Therapy for Acute Ischaemic Stroke (2001) Thrombolytic therapy for acute ischaemic stroke. Canadian Journal of Emergency Medicine, 3, Brott T, Riggs J & Hachinski V (1996) Controversies in Neurology. Thrombolysis for Stroke Archives of Neurology, 53, Caplan L, Mohr J, Kistler J & Grotta J (1998) Clinical debate: Should Thrombolytic Therapy Be the First- Line Treatment for Acute Ischemic Stroke? NEJM, 337, (correspondence NEJM, 338, 761 3). Chen ZM, Sandercock P, Pan HC et al. (2000) on behalf of the CAST and IST Collaborative Groups Indications for early aspirin use in acute ischaemic stroke. A combined analysis of randomised patients from the Chinese Acute Stroke Trail and the International Stroke Trial. Stroke, 31, Cochrane Stroke Review Group (1999) Collaborative Review Group Search Strategy. In: The Cochrane Library: Issue 4. Update Software, Oxford. (Updated quarterly.) Counsell C, Warlow C, Sandercock P, Fraser H & van Gijn J (1995) The Cochrane Collaboration Stroke Review Group. Meeting the Need for Systematic Reviews in Stroke Care. Stroke, 26, Evenson B (1999) Clot-busting stroke drug saving lives. The National Post, February, 1 3 (section A). Fibrinolytic Therapy Trialists (FTT) Collaborative Group (1994). Indications for fibrinolytic therapy in suspected acute myocardial infarction; collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Lancet, 343, Foss K (1999) Promise and perils at a stroke. The Globe and Mail, 16 February (1), 7 8 (section c). Gorman C (1996) A Quick Fix for Strokes: Heart experts advise doctors on how to make better use of a powerful clot-busting agent. Time Magazine, 16 September (148). Available online at time/magazine/archive/1996/dom/960916/ medicine.html. Gubitz GJ, Sandercock PAG (1999) Management and Secondary Prevention of Acute Ischaemic Stroke. In: Clinical Evidence: a Compendium of the Best Available Evidence for Effective Health Care (Issue 1) (ed Godlee F), pp , BMJ Publishing Group, London. Hacke W, Kaste M, Fieschi C et al. for the ECASS Study Group. (1995) Intravenous thrombolysis with recombinant tissue plasminogen activator for acute hemispheric stroke. The European Cooperative Acute Stroke Study (ECASS). Journal of the American Medical Association, 274, Hacke W, Kaste M, Fieschi C et al. for the Second European-Australasian Acute Stroke Study Investigators. (1998) Randomised double-blind placebo-controlled trial of thrombolytic therapy with intravenous alteplase in acute ischaemic stroke (ECASS II). The Lancet, 352, Hill MD & Hachinski V (1998) Stroke treatment: time is brain. Lancet, 352 (Suppl. III), Horowitz SH (1998) Thrombolytic therapy in acute stroke: Neurologists, Get off your hands!. Archives of Neurology, 55, Li J (1998) Emergency Forum. Question Thrombolytic Use for Cerebrovascular Accidents. Journal of Emerg Medy, 16, MacKinlay S (1999) Stroke drug heals, harms at QEII. The Daily News, 13 February, 7. National Broadcasting Corporation (1997) ER episode: Random Acts. Summary available from: National Institute of Neurological Disorders and Stroke rt-pa Study Group (1995) Tissue plasminogen activator for the treatment of acute ischaemic stroke. NEJM, 333, National Stroke Association (1993) Consensus Statement. Stroke: the first six hours. Emergency Evaluation and Treatment. Stroke Clinical Updates. Journal of Stroke Cerebrovasc Disease, 3, or Norris JW, Buchan A, Cote R et al. (1998) Canadian Guidelines for Intravenous Thrombolytic Treatment in Acute Stroke. A Consensus Statement of the Canadian Stroke Consortium. Canadian Journal of Neurological Science, 25, Pessin MS, Adams HP, Adams RJ et al. (1997) American Heart Association Prevention Conference IV. Prevention and Rehabilitation of Stroke; Acute Interventions. Stroke, 28, Royal College of Physicians of Edinburgh (1999) Consensus Conference on Medical Management of Stroke May 1998 Journal of Neurology, Neurosurgery and Psychiatry, 66, Stroke Unit Trialists Collaboration (2001) Organised inpatient (stroke unit) care for stroke (Cochrane Review). In: The Cochrane Library: Issue 4. Update Software, Oxford. Wardlaw J & Warlow C (1992) Thrombolysis in Acute Ischaemic Stroke: Does it Work? Stroke, 23, Wardlaw JM, Yamaguchi T & del Zoppo G (2001) Thrombolytic therapy versus control for acute ischaemic stroke. (Cochrane Review). In: The Cochrane Library: Issue 4. Update Software, Oxford. Wester P, Radberg J, Lundgren B, Peltonen M, for the Seek-Medical-Attention-in-Time Study Group (1999) Factors Associated With Delayed Admission to Hospital and In-Hospital Delays in Acute Stroke and TIA. A Prospective, Multicentre Study. Stroke, 30, 40 8.
An Updated Systematic Review of rt-pa in Acute Ischaemic Stroke
Wardlaw An Updated Systematic Review of rt-pa in Acute Ischaemic Stroke Joanna M Wardlaw COMPETING INTERESTS The author is on the Steering Committees of the Third International Stroke Trial (IST3) and
More informationBritish Geriatrics Society
Healthcare professional group/clinical specialist statement Thank you for agreeing to give us a statement on your organisation s view of the technology and the way it should be used in the NHS. Healthcare
More informationSetting The setting was secondary care. The study was carried out in the UK, with emphasis on Scottish data.
Cost-effectiveness of thrombolysis with recombinant tissue plasminogen activator for acute ischemic stroke assessed by a model based on UK NHS costs Sandercock P, Berge E, Dennis M, Forbes J, Hand P, Kwan
More informationTechnology appraisal guidance Published: 26 September 2012 nice.org.uk/guidance/ta264
Alteplase for treating acute ischaemic stroke Technology appraisal guidance Published: 26 September 2012 nice.org.uk/guidance/ta264 NICE 2018. All rights reserved. Subject to Notice of rights (https://www.nice.org.uk/terms-and-conditions#notice-ofrights).
More informationThis booklet has been published by CREST (the Clinical Resource Efficiency Support Team).
This booklet has been published by CREST (the Clinical Resource Efficiency Support Team). CREST is a small committee of health care professionals established under the auspices of the Central Medical Advisory
More informationCerebrovascular Disease lll. Acute Ischemic Stroke. Use of Intravenous Alteplace in Acute Ischemic Stroke Louis R Caplan MD
Cerebrovascular Disease lll. Acute Ischemic Stroke Use of Intravenous Alteplace in Acute Ischemic Stroke Louis R Caplan MD Thrombolysis was abandoned as a stroke treatment in the 1960s due to an unacceptable
More informationSetting The setting was secondary care. The economic analysis was conducted in Vancouver, Canada.
Cost-utility analysis of tissue plasminogen activator therapy for acute ischaemic stroke Sinclair S E, Frighetto, Loewen P S, Sunderji R, Teal P, Fagan S C, Marra C A Record Status This is a critical abstract
More informationJournal Club. 1. Develop a PICO (Population, Intervention, Comparison, Outcome) question for this study
Journal Club Articles for Discussion Tissue plasminogen activator for acute ischemic stroke. The National Institute of Neurological Disorders and Stroke rt-pa Stroke Study Group. N Engl J Med. 1995 Dec
More informationBath, Philip M.W. and England, Timothy J. (2009) Thighlength compression stockings and DVT after stroke. Lancet. ISSN (In Press)
Bath, Philip M.W. and England, Timothy J. (2009) Thighlength compression stockings and DVT after stroke. Lancet. ISSN 0140-6736 (In Press) Access from the University of Nottingham repository: http://eprints.nottingham.ac.uk/1087/1/lancet_clots_1_20090522_4.pdf
More informationAcute ischemic stroke is a major cause of morbidity
Outcomes of Treatment with Recombinant Tissue Plasminogen Activator in Patients Age 80 Years and Older Presenting with Acute Ischemic Stroke Jennifer C. Drost, DO, MPH, and Susana M. Bowling, MD ABSTRACT
More informationThrombolysis in acute stroke
152 Thrombolysis in acute stroke Cerebrovascular disease has a major impact on people s physical, social and mental well-being, and is a major financial burden on the NHS. In recent times, the management
More informationGuideline scope Stroke and transient ischaemic attack in over 16s: diagnosis and initial management (update)
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Guideline scope Stroke and transient ischaemic attack in over s: diagnosis and initial management (update) 0 0 This will update the NICE on stroke and
More informationCanadian Best Practice Recommendations for Stroke Care. (Updated 2008) Section # 3 Section # 3 Hyperacute Stroke Management
Canadian Best Practice Recommendations for Stroke Care (Updated 2008) Section # 3 Section # 3 Hyperacute Stroke Management Reorganization of Recommendations 2008 2006 RECOMMENDATIONS: 2008 RECOMMENDATIONS:
More informationMechanical thrombectomy in Plymouth. Will Adams. Will Adams
Mechanical thrombectomy in Plymouth Will Adams Will Adams History Intra-arterial intervention 1995 (NINDS) iv tpa improved clinical outcome in patients treated within 3 hours of ictus but limited recanalisation
More informationNQF ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE. Measure Information Form Collected For: The Joint Commission Only CMS Voluntary Only
Last Updated: Version 4.4a NQF ENDORSED VOLUNTARY CONSENSUS STANDARDS FOR HOSPITAL CARE Measure Set: Stroke (STK) Set Measure ID #: Measure Information Form Collected For: The Joint Commission Only CMS
More informationAcute stroke thrombolysis with intravenous tissue plasminogen activator in an Australian tertiary hospital
Acute stroke thrombolysis with intravenous tissue plasminogen activator in an Australian tertiary hospital STROKE IS THE MOST common cause of permanent disability in the Australian community The Medical
More informationThrombolytic Therapy in Clinical Practice The Norwegian Experience
Thrombolytic Therapy in Clinical Practice The Norwegian Experience Thomassen Lars Thomassen, Ulrike Waje-Andreassen, Halvor Næss ABSTRACT Background: Awaiting the European approval of thrombolysis, we
More informationAcute Stroke Care: the Nuts and Bolts of it. ECASS I and II ATLANTIS. Chris V. Fanale, MD Colorado Neurological Institute Swedish Medical Center
Acute Stroke Care: the Nuts and Bolts of it Chris V. Fanale, MD Colorado Neurological Institute Swedish Medical Center ECASS I and II tpa for patients presenting
More informationReview Article Medicolegal Considerations with Intravenous Tissue Plasminogen Activator in Stroke: A Systematic Review
Stroke Research and Treatment Volume 2013, Article ID 562564, 6 pages http://dx.doi.org/10.1155/2013/562564 Review Article Medicolegal Considerations with Intravenous Tissue Plasminogen Activator in Stroke:
More informationPrediction of Hemorrhage in Acute Ischemic Stroke Using Permeability MR Imaging
AJNR Am J Neuroradiol 26:2213 2217, October 2005 Technical Note Prediction of Hemorrhage in Acute Ischemic Stroke Using Permeability MR Imaging Andrea Kassner, Timothy Roberts, Keri Taylor, Frank Silver,
More informationRe: Delivering Safe and Sustainable Clinical Services Green Paper Rebuilding Tasmania s Health System
By email: onehealthsystem@dhhs.tas.gov.au To whom it may concern Re: Delivering Safe and Sustainable Clinical Services Green Paper Rebuilding Tasmania s Health System I am pleased to provide this response
More informationStroke Update. Lacunar 19% Thromboembolic 6% SAH 13% ICH 13% Unknown 32% Hemorrhagic 26% Ischemic 71% Other 3% Cardioembolic 14%
Stroke Update Michel Torbey, MD, MPH, FAHA, FNCS Medical Director, Neurovascular Stroke Center Professor Department of Neurology and Neurosurgery The Ohio State University Wexner Medical Center Objectives
More information7 TI - Epidemiology of intracerebral hemorrhage.
1 TI - Multiple postoperative intracerebral haematomas remote from the site of craniotomy. AU - Rapana A, et al. SO - Br J Neurosurg. 1998 Aug;1():-8. Review. IDS - PMID: 1000 UI: 991958 TI - Cerebral
More informationTherapy for Acute Stroke. Systems of Care for TIA
Therapy for Acute Stroke and Systems of Care for TIA Gregory W. Albers, MD Coyote Foundation Professor of Neurology and Neurological Sciences Director, Stanford Stroke Center Stanford University Medical
More informationThe tpa Cage Match. Disclosures. Cage Match. Cage Match 1/27/2014. January 8, Advisory Boards
The tpa Cage Match January 8, 2014 Andy Jagoda, MD, FACEP Professor and Chair of Emergency Medicine Mount Sinai School of Medicine New York, New York Advisory Boards Disclosures Astra Zeneca, Pfizer, CSL
More informationFOCUS: Fluoxetine Or Control Under Supervision Results. Martin Dennis on behalf of the FOCUS collaborators
FOCUS: Fluoxetine Or Control Under Supervision Results Martin Dennis on behalf of the FOCUS collaborators Background Pre clinical and imaging studies had suggested benefits from fluoxetine (and other SSRIs)
More informationDr Ben Turner. Consultant Neurologist and Honorary Senior Lecturer Barts and The London NHS Trust London Bridge Hospital
Stroke Management Dr Ben Turner Consultant Neurologist and Honorary Senior Lecturer Barts and The London NHS Trust London Bridge Hospital Introduction Stroke is the major cause of disability in the developed
More informationIntervention: ARNI rehabilitation technique delivered by trained individuals. Assessment will be made at 3, 6 and 12 months.
PRIORITY BRIEFING The purpose of this briefing paper is to aid Stakeholders in prioritising topics to be taken further by PenCLAHRC as the basis for a specific evaluation or implementation projects. QUESTION
More informationQuality ID #187: Stroke and Stroke Rehabilitation: Thrombolytic Therapy National Quality Strategy Domain: Effective Clinical Care
Quality ID #187: Stroke and Stroke Rehabilitation: Thrombolytic Therapy National Quality Strategy Domain: Effective Clinical Care 2018 OPTIONS FOR INDIVIDUAL MEASURES: REGISTRY ONLY MEASURE TYPE: Process
More informationClinical specialist statement. Thank you for agreeing to give us a statement on your view of the technology and the way it should be used in the NHS.
Clinical specialist statement Thank you for agreeing to give us a statement on your view of the technology and the way it should be used in the NHS. Healthcare professionals can provide a unique perspective
More informationInterrater Reliability and Sensitivity of CT Interpretation by Physicians Involved in Acute Stroke Care
Detection of Early CT Signs of >1/3 Middle Cerebral Artery Infarctions Interrater Reliability and Sensitivity of CT Interpretation by Physicians Involved in Acute Stroke Care Mary A. Kalafut, MD; David
More informationMaximising Delivery of Thrombectomy
Maximising Delivery of Thrombectomy Professor Gary Ford Chief Executive Officer, Oxford Academic Health Science Network Consultant Stroke Physician, Oxford University Hospitals Visiting Professor of Clinical
More informationOutlook for intracerebral haemorrhage after a MISTIE spell
Outlook for intracerebral haemorrhage after a MISTIE spell David J Werring PhD FRCP Stroke Research Centre, Department of Brain Repair and Rehabilitation, UCL Institute of Neurology, National Hospital
More informationEmergency Department Management of Acute Ischemic Stroke
Emergency Department Management of Acute Ischemic Stroke R. Jason Thurman, MD Associate Professor of Emergency Medicine and Neurosurgery Associate Director, Vanderbilt Stroke Center Vanderbilt University,
More informationIMAGING IN ACUTE ISCHEMIC STROKE
IMAGING IN ACUTE ISCHEMIC STROKE Timo Krings MD, PhD, FRCP (C) Professor of Radiology & Surgery Braley Chair of Neuroradiology, Chief and Program Director of Diagnostic and Interventional Neuroradiology;
More informationThe impact of pre-alert on stroke thrombolysis door to needle time
The impact of pre-alert on stroke thrombolysis door to needle time John Reid - Stroke Neurologist Alexander Bown - GPST1 Andrew Barrett - 4 th year Medical student Aberdeen Royal Infirmary "Top-speed Bradford
More informationMedico-Legal Aspects of Using Tissue Plasminogen Activator in Acute Ischemic Stroke
Current Treatment Options in Cardiovascular Medicine (2011) 13:233 239 DOI 10.1007/s11936-011-0122-0 Cerebrovascular Disease and Stroke Medico-Legal Aspects of Using Tissue Plasminogen Activator in Acute
More informationThe administration of intravenous tissue plasminogen
Intravenous Tissue Plasminogen Activator for Acute Ischemic Stroke A Canadian Hospital s Experience Kristine M. Chapman, MD; Andrew R. Woolfenden, MD; Douglas Graeb, MD; Dean C.C. Johnston, MD; Jeff Beckman,
More informationEmergency Management of Acute Ischemic Stroke in Incapacitated Patients Who Have No Surrogate Decision Makers Fred Rincon, MD, MSc
Ethical Perspectives Emergency Management of Acute Ischemic Stroke in Incapacitated Patients Who Have No Surrogate Decision Makers Fred Rincon, MD, MSc Address correspondence to Dr Fred Rincon, Department
More informationSafety and feasibility of intravenous thrombolytic therapy in Iranian patients with acute ischemic stroke
Original Article Medical Journal of the Islamic Republic of Iran, Vol. 27, No. 3, Aug 2013, pp. 113-118 Safety and feasibility of intravenous thrombolytic therapy in Iranian patients with acute ischemic
More informationAVERT Trial Debate: Implications for Practice Have we AVERT ed the real message?
AVERT Trial Debate: Implications for Practice Have we AVERT ed the real message? Jackie Bosch, PhD, OT Reg(Ont) School of Rehabilitation Science McMaster University Vince DePaul PT PhD School of Rehabilitation
More informationCONCISE GUIDE National Clinical Guidelines for Stroke 2nd Edition
CONCISE GUIDE 2004 National for Stroke 2nd Edition This concise guide summarises the recommendations, graded according to the evidence, from the National 2nd edition. As critical aspects of care are not
More informationBlood Pressure Variability and Hemorrhagic Transformation after Intravenous Thrombolysis in Acute Ischemic Stroke
www.jneurology.com Neuromedicine www.jneurology.com Research Article Open Access Blood Pressure Variability and Hemorrhagic Transformation after Intravenous Thrombolysis in Acute Ischemic Stroke Hanna
More informationIMAGING IN ACUTE ISCHEMIC STROKE
IMAGING IN ACUTE ISCHEMIC STROKE Timo Krings MD, PhD, FRCP (C) Professor of Radiology & Surgery Braley Chair of Neuroradiology, Chief and Program Director of Diagnostic and Interventional Neuroradiology;
More informationSpecific Standards of Accreditation for Residency Programs in Adult and Pediatric Neurology
Specific Standards of Accreditation for Residency Programs in Adult and Pediatric Neurology INTRODUCTION 2011 A university wishing to have an accredited program in adult Neurology must also sponsor an
More informationDawn Matherne Meyer PhD,RN,FNP-C. Assistant Professor University of California San Diego
Dawn Matherne Meyer PhD,RN,FNP-C Assistant Professor University of California San Diego Evidence Based Care of the Stroke Patient: A Focus on Acute Treatment, BP Management, & Antiplatelets TIME IS BRAIN
More informationBY MARILYN M. RYMER, MD
Lytics, Devices, and Advanced Imaging The evolving art and science of acute stroke intervention. BY MARILYN M. RYMER, MD In 1996, when the US Food and Drug Administration (FDA) approved the use of intravenous
More informationMeeting the Future Challenge of Stroke
Meeting the Future Challenge of Stroke Stroke Medicine Consultant Workforce Requirements 2011 201 Dr Christopher Price BASP Training and Education Committee Stroke Medicine Specialist Advisory Committee
More informationAlteplase for the treatment of acute ischaemic stroke (review of technology appraisal 122)
Alteplase for the treatment of acute ischaemic stroke (review of technology appraisal 122) Produced by School of Health and Related Research (ScHARR), The University of Sheffield Authors Sarah Davis, ScHARR,
More informationBuilding a Stroke Portfolio. June 28, 2018
Building a Stroke Portfolio June 28, 2018 1 Forward-Looking Statements This presentation contains forward-looking statements, including statements relating to: the potential benefits, safety and efficacy
More informationTissue Plasminogen Activator Overdose in Acute Ischemic Stroke Patients Linked to Poorer Functional Outcomes
Tissue Plasminogen Activator Overdose in Acute Ischemic Stroke Patients Linked to Poorer Functional Outcomes Demetrios J. Sahlas, MSc, MD,* Linda Gould, RPN, Richard H. Swartz, MD, PhD, Naufal Mohammed,
More informationList of Exhibits Adult Stroke
List of Exhibits Adult Stroke List of Exhibits Adult Stroke i. Ontario Stroke Audit Hospital and Patient Characteristics Exhibit i. Hospital characteristics from the Ontario Stroke Audit, 200/ Exhibit
More informationRBWH ICU Journal Club February 2018 Adam Simpson
RBWH ICU Journal Club February 2018 Adam Simpson 3 THROMBOLYSIS Reperfusion therapy has become the mainstay of therapy for ischaemic stroke. Thrombolysis is now well accepted within 4.5 hours. - Improved
More informationTable 1. Specific changes to the FDA labeling for recombinant tissue plasminogen activator (Alteplase, Activase, Genentech, inc).
Acute Ischemic Stroke Controversies Steven R. Messé, MD, FAAN Associate professor of Neurology, Pereleman School of Medicine at the University of Pennsylvania, Philadelphia, PA Using the term controversy
More informationfor Stroke Care (Update 2013)
Overview (Version 1.0) May 23 rd, 2013 Page 1 TAKING ACTION TOWARDS OPTIMAL STROKE CARE 2 Table of Contents Section Content Page About this Resource 3 1.0 Overview 4 1.1 Purpose of the Resource Kit 4 2.0
More informationAppendix A: Summary of evidence from surveillance
Appendix A: Summary of evidence from surveillance 8-year surveillance (2016) stroke and transient ischaemic attack in over 16s (2008) NICE guideline CG68 Summary of new evidence from surveillance... 1
More informationAntithrombotics: Percent of patients with an ischemic stroke or TIA prescribed antithrombotic therapy at discharge. Corresponding
Get With The Guidelines -Stroke is the American Heart Association s collaborative performance improvement program, demonstrated to improve adherence to evidence-based care of patients hospitalized with
More informationStroke Systems of Care
Comprehensive Stroke and Cerebrovascular Center Stroke Systems of Care Dana Stradling RN MSN CNRN UC Irvine Stroke Manager dstradli@uci.edu Why Stroke Systems? No. 4 th 5 th cause of death in the U.S.
More informationACUTE STROKE IMAGING
ACUTE STROKE IMAGING Mahesh V. Jayaraman M.D. Director, Inter ventional Neuroradiology Associate Professor Depar tments of Diagnostic Imaging and Neurosurger y Alper t Medical School at Brown University
More informationAntithrombotic therapy in patients with transient ischemic attack / stroke (acute phase <48h)
Antithrombotic therapy in patients with transient ischemic attack / stroke (acute phase
More informationASCEND Randomized placebo-controlled trial of aspirin 100 mg daily in 15,480 patients with diabetes and no baseline cardiovascular disease
ASCEND Randomized placebo-controlled trial of aspirin 100 mg daily in 15,480 patients with diabetes and no baseline cardiovascular disease Jane Armitage and Louise Bowman on behalf of the ASCEND Study
More informationUpdate on Stroke in South Carolina: REACHing to Treat More Patients using Telestroke
Update on Stroke in South Carolina: REACHing to Treat More Patients using Telestroke 1 Robert J Adams MS MD Professor of Neuroscience University Eminent Scholar Director South Carolina Center of Economic
More informationCanadian Stroke Best Practices Initial ED Evaluation of Acute Stroke and Transient Ischemic Attack (TIA) Order Set (Order Set 1)
Canadian Best Practice Recommendations for Stroke Care: All patients presenting to an emergency department with suspected stroke or transient ischemic attack must have an immediate clinical evaluation
More informationENCHANTED Era: Is it time to rethink treatment of acute ischemic stroke? Kristin J. Scherber, PharmD, BCPS Emergency Medicine Clinical Pharmacist
ENCHANTED Era: Is it time to rethink treatment of acute ischemic stroke? Kristin J. Scherber, PharmD, BCPS Emergency Medicine Clinical Pharmacist Pharmacy Grand Rounds 26 July 2016 2015 MFMER slide-1 Learning
More informationTHE QUARTERLY NEWSLETTER OF THE NEUROVASCULAR STROKE CENTER AT THE OHIO STATE UNIVERSITY
THE QUARTERLY NEWSLETTER OF THE NEUROVASCULAR STROKE CENTER AT THE OHIO STATE UNIVERSITY SPRING 2012 FROM THE EDITORS Michel T. Torbey, MD, MPH, FCCM, FAHA Professor of Neurology & Neurosurgery Medical
More informationWhat can we learn from the AVERT trial (so far)?
South West Stroke Network Event, 29 th April, 2015 What can we learn from the AVERT trial (so far)? Peter Langhorne, Professor of stroke care, Glasgow University Disclosure PL was AVERT investigator and
More informationDiagnostic and Therapeutic Consequences of Repeat Brain Imaging and Follow-up Vascular Imaging in Stroke Patients
AJNR Am J Neuroradiol 0:7, January 999 Diagnostic and Therapeutic Consequences of Repeat Brain Imaging and Follow-up Vascular Imaging in Stroke Patients Birgit Ertl-Wagner, Tobias Brandt, Christina Seifart,
More informationRisk Factors for Ischemic Stroke: Electrocardiographic Findings
Original Articles 232 Risk Factors for Ischemic Stroke: Electrocardiographic Findings Elley H.H. Chiu 1,2, Teng-Yeow Tan 1,3, Ku-Chou Chang 1,3, and Chia-Wei Liou 1,3 Abstract- Background: Standard 12-lead
More informationNeuro-vascular Intervention in Stroke. Will Adams Consultant Neuroradiologist Plymouth Hospitals NHS Trust
Neuro-vascular Intervention in Stroke Will Adams Consultant Neuroradiologist Plymouth Hospitals NHS Trust Stroke before the mid 1990s Swelling Stroke extension Haemorrhagic transformation Intravenous thrombolysis
More informationStents, Scans and Stem Cells: Current and Future Stroke Treatment and Research
Stents, Scans and Stem Cells: Current and Future Stroke Treatment and Research Prof Keith W Muir Institute of Neuroscience & Psychology University of Glasgow Institute of Neurological Sciences Queen Elizabeth
More informationEffectiveness and cost-effectiveness of thrombolysis in submassive pulmonary embolism Perlroth D J, Sanders G D, Gould M K
Effectiveness and cost-effectiveness of thrombolysis in submassive pulmonary embolism Perlroth D J, Sanders G D, Gould M K Record Status This is a critical abstract of an economic evaluation that meets
More informationQQUIP and the Quality Enhancing Interventions project
QQUIP and the Quality Enhancing Interventions project QQUIP (Quest for Quality and Improved Performance) is a five-year research initiative of The Health Foundation. QQUIP provides independent reports
More informationUpdated Stroke Clinical Handbook: Endovascular Treatment (EVT) and what it means for me
Updated Stroke Clinical Handbook: Endovascular Treatment (EVT) and what it means for me Dr Grant Stotts, Co-Chair, Provincial Endovascular Treatment Steering Committee March 29, 2017 Beth Linkewich, Provincial
More informationFurther data analysis topics
Further data analysis topics Jonathan Cook Centre for Statistics in Medicine, NDORMS, University of Oxford EQUATOR OUCAGS training course 24th October 2015 Outline Ideal study Further topics Multiplicity
More informationDiagnosis and Treatment of Deep Venous Thrombosis and Pulmonary Embolism
Agency for Healthcare Research and Quality Evidence Report/Technology Assessment Diagnosis and Treatment of Deep Venous Thrombosis and Pulmonary Embolism Summary Number 68 Overview Venous thromboembolism
More informationWhen the learner has completed this module, she/he will be able to:
Thrombolytics and Myocardial Infarction WWW.RN.ORG Reviewed September 2017, Expires September 2019 Provider Information and Specifics available on our Website Unauthorized Distribution Prohibited 2017
More informationStroke in the Rural Setting: How You Can Make A Difference. Susie Fisher, RN, BSN Program Manager Providence Stroke Center Portland, OR
Stroke in the Rural Setting: How You Can Make A Difference. Susie Fisher, RN, BSN Program Manager Providence Stroke Center Portland, OR Outline State Statistics The Oregon Problem Time & Treatments Steps
More informationMohamed Al-Khaled, MD,* Christine Matthis, MD, and J urgen Eggers, MD*
Predictors of In-hospital Mortality and the Risk of Symptomatic Intracerebral Hemorrhage after Thrombolytic Therapy with Recombinant Tissue Plasminogen Activator in Acute Ischemic Stroke Mohamed Al-Khaled,
More informationDrano vs. MR CLEAN Review of New Endovascular Therapy for Acute Ischemic Stroke Patients
Drano vs. MR CLEAN Review of New Endovascular Therapy for Acute Ischemic Stroke Patients Peter Panagos, MD, FACEP, FAHA Associate Professor Emergency Medicine and Neurology Washington University School
More informationIndications for Early Aspirin Use in Acute Ischemic Stroke
Indications for Early Aspirin Use in Acute Ischemic Stroke A Combined Analysis of 40 000 Randomized Patients From the Chinese Acute Stroke Trial and the International Stroke Trial ZhengMing Chen, MBBS,
More informationHospital Utilization of Thrombolysis for the Treatment of Acute Ischaemic Stroke
IBIMA Publishing Research in Neurology: An International Journal http://www.ibimapublishing.com/journals/rnij/rnij.html Vol. 2013 (2013), Article ID 369047, 10 pages DOI: 10.5171/2013.369047 Research Article
More informationCritical Review Form Therapy
Critical Review Form Therapy A transient ischaemic attack clinic with round-the-clock access (SOS-TIA): feasibility and effects, Lancet-Neurology 2007; 6: 953-960 Objectives: To evaluate the effect of
More informationTRANSIENT ISCHEMIC ATTACK (TIA)
TRANSIENT ISCHEMIC ATTACK (TIA) AND MINOR STROKE Dr. Leanne K. Casaubon, MD MSc FRCPC Associate Professor, University of Toronto Director, TIA and Minor Stroke (TAMS) Unit University Health Network - Toronto
More informationIs hospitalization after TIA cost-effective on the basis of treatment with tpa? Nguyen Huynh M N, Johnston S C
Is hospitalization after TIA cost-effective on the basis of treatment with tpa? Nguyen Huynh M N, Johnston S C Record Status This is a critical abstract of an economic evaluation that meets the criteria
More informationStroke Clinical Trials Update Transitioning to an Anatomic Diagnosis in Ischemic Stroke
Stroke Clinical Trials Update Transitioning to an Anatomic Diagnosis in Ischemic Stroke Alexander A. Khalessi MD MS Director of Endovascular Neurosurgery Surgical Director of NeuroCritical Care University
More informationAn introduction to Quality by Design. Dr Martin Landray University of Oxford
An introduction to Quality by Design Dr Martin Landray University of Oxford Criteria for a good trial Ask an IMPORTANT question Answer it RELIABLY Quality Quality is the absence of errors that matter to
More informationAcute Ischaemic Stroke Pathways Drip and Ship
Acute Ischaemic Stroke Pathways Drip and Ship Professor Gary Ford Chief Executive Officer, Oxford Academic Health Science Network Consultant Stroke Physician, Oxford University Hospitals Visiting Professor
More informationWAKE-UP has received funding from the European Union Seventh Framework Programme (FP7/ ) under grant agreement n
Intravenous Thrombombolysis in Stroke Patients with Unknown Time of Onset Results of the Multicentre, Randomized, Double-blind, Placebo- Controlled WAKE-UP Trial G. Thomalla, C.Z. Simonsen, F. Boutitie,
More informationJointly provided by Potomac Center for Medical Education and Rockpointe Supported by an educational grant from Genentech, A Member of the Roche Group
Jointly provided by Potomac Center for Medical Education and Rockpointe Supported by an educational grant from Genentech, A Member of the Roche Group Faculty Speakers Deepak L. Bhatt, MD, MPH, FACC, FAHA,
More informationEndovascular therapy using mechanical thrombectomy devices for treatment of patients with ischaemic stroke
Evidence Note 87 December 2018 In response to enquiry from the Thrombectomy Advisory Group Endovascular therapy using mechanical thrombectomy devices for treatment of patients with ischaemic stroke Questions
More informationLa terapia antiaggregante nel paziente con stroke
La terapia antiaggregante nel paziente con stroke Paolo Gresele Dipartimento di Medicina, Sez. Medicina Interna e Cardiovascolare Università di Perugia XXVII Congresso Nazionale FCSA Milano, 20-22 Ottobre
More informationCritical Review Form Therapy Objectives: Methods:
Critical Review Form Therapy Clinical Trial Comparing Primary Coronary Angioplasty with Tissue-Plasminogen Activator for Acute Myocardial Infarction (GUSTO-IIb), NEJM 1997; 336: 1621-1628 Objectives: To
More informationSentinel Stroke National Audit Programme (SSNAP) Based on stroke patients admitted to hospital for thrombectomy between April 2016 and March 2017
Thrombectomy Sentinel Stroke National Audit Programme (SSNAP) Thrombectomy Report for April 2016 - March 2017 National results July 2017 Based on stroke patients admitted to hospital for between April
More informationWhite Rose Research Online URL for this paper: Version: Accepted Version
This is a repository copy of Alteplase for the Treatment of Acute Ischaemic Stroke: A NICE Single Technology Appraisal; an Evidence Review Group Perspective. White Rose Research Online URL for this paper:
More informationEmergency Department Stroke Registry Process of Care Indicator Specifications (July 1, 2011 June 30, 2012 Dates of Service)
Specifications Description Methodology NIH Stroke Scale (NIHSS) Performed in Initial Evaluation used to assess the percentage of adult stroke patients who had the NIHSS performed during their initial evaluation
More informationEmergency Treatment of Ischemic Stroke
Emergency Treatment of Ischemic Stroke JEFFREY BOYLE, M.D., PHD CLINICAL DIRECTOR OF STROKE AT AVERA MCKENNAN AVERA MEDICAL GROUP NEUROLOGY SIOUX FALLS, SD Conflicts of Interest None I will discuss therapies
More informationACR OA Guideline Development Process Knee and Hip
ACR OA Guideline Development Process Knee and Hip 1. Literature searching frame work Literature searches were developed based on the scenarios. A comprehensive search strategy was used to guide the process
More informationAcute Stroke Management 2009
Acute Stroke Management 2009 Saving the Brain Conference Royal York Hotel January 24, 2009 Frank L. Silver, MD, FRCPC Director, Toronto West Stroke Program Professor of Medicine (Neurology) University
More informationTime delays in instituting thrombolysis in acute myocardial infarction - a Singapore perspective
Hong Kong Journal of Emergency Medicine Time delays in instituting thrombolysis in acute myocardial infarction - a Singapore perspective M Tiru and SH Goh The reduction of mortality from acute myocardial
More information